Goldman Sachs has appointed insiders William Connolly and Michael Voris as co-heads of Equity Capital Markets (ECM) in the ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Investors, shrugging off ongoing concerns around trade and inflation, are searching for the next catalyst to send stocks ...

These three premier ASX healthcare stocks just reported half-yearly earnings – and each saw its share price dip…So, is now the time to buy?

Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer ...

Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Thank you, Kevin. Good morning, everyone, ...

Meanwhile, Goldman Sachs lifted its 12-month price target for Europe’s STOXX 600 to 580 from 540, citing potential benefits from a Ukraine peace deal, such as lower risk premiums, reduced energy costs ...

Major indices delivered a mixed performance on Friday after Donald Trump announced new "reciprocal tariffs" on a number of ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for canceled manufacturing contract. Goldman Sachs US Biotechnology Analyst Salveen Richter ...